Web: Novartis external link
Location: Basel
Discipline: Medicine/Pharmacology
Related to:

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.

Medicine May 21
Study in patients with advanced nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin met primary endpoint - Full results will be submitted for presentation at a major medical meeting; worldwide regulatory filings are planned for 2015 - Afinitor is already approved in more than 95 countries for patients with advanced pancreatic NET, a rare form of can
Medicine May 20

QVA149 improved lung function, breathlessness and health-related quality of life in moderate-to-severe COPD patients, according to EXPEDITION trial results - GEM 1 & 2 studies showed NVA237 provided significant and clinically meaningful improvements in lung function in moderat

Medicine Apr 27

Positive top-line results seen with Arzerra plus fludarabine and cyclophosphamide in chronic lymphocytic leukemia (CLL) patients when initial treatment stopped working - CLL is the most commonly diagnosed adult leukemia in Western countries, accounting for approximately 1 in 4 cases of al

Medicine Apr 21

More than 27,000 Novartis associates worldwide dedicate an estimated 200,000 hours to volunteer with charitable causes in their communities - Community Partnership Day symbolizes the company's commitment to improving health and serving its local communities - Associates are partic

Medicine May 8

Zykadia (ceritinib) is the first treatment option approved for patients in Europe with ALK+ NSCLC previously treated with the ALK inhibitor crizotinib - Marketing authorization was based on two studies demonstrating Zykadia shrank tumors in ALK+ NSCLC patients who received prior crizotini

Business Apr 23

Continuing operations saw sales, core operating income and core EPS grow (cc ) in Q1 - Net sales were USD 11.9 billion (-7%, +3% cc) - Operating income was USD 2.8 billion (-1%, +15% cc) - Core operating income (-4%, +9% cc) grew faster than sales (cc), resulting in core margin of 30.6

Medicine Apr 21

New FREEDOMS/FREEDOMS II sub-group analysis showed Gilenya-treated patients were six-times more likely to achieve 'no evidence of disease activity (NEDA4)' vs placebo - NEDA4 is based on four key measures of relapsing MS (RMS): relapses, MRI lesions, MS-related brain shrinkage and di

website preview


Medicine and Life Sciences

Logo Careerjet